MacroGenics (MGNX) Competitors $1.58 +0.02 (+1.28%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.56 -0.03 (-1.58%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. ARCT, GLUE, HUMA, CYRX, INBX, TNXP, FHTX, CADL, AURA, and ABEOShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Humacyte (HUMA), CryoPort (CYRX), Inhibrx Biosciences (INBX), Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Arcturus Therapeutics Monte Rosa Therapeutics Humacyte CryoPort Inhibrx Biosciences Tonix Pharmaceuticals Foghorn Therapeutics Candel Therapeutics Aura Biosciences Abeona Therapeutics Arcturus Therapeutics (NASDAQ:ARCT) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has more risk & volatility, ARCT or MGNX? Arcturus Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Which has preferable valuation & earnings, ARCT or MGNX? MacroGenics has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$131.27M2.54-$80.94M-$2.53-4.86MacroGenics$152.43M0.65-$66.97M-$0.89-1.78 Is ARCT or MGNX more profitable? MacroGenics has a net margin of -36.23% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-47.47% -27.41% -19.01% MacroGenics -36.23%-59.84%-23.45% Do insiders & institutionals have more ownership in ARCT or MGNX? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 13.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend ARCT or MGNX? Arcturus Therapeutics currently has a consensus target price of $54.00, indicating a potential upside of 339.02%. MacroGenics has a consensus target price of $5.33, indicating a potential upside of 237.55%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11MacroGenics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Does the media refer more to ARCT or MGNX? In the previous week, Arcturus Therapeutics had 1 more articles in the media than MacroGenics. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for MacroGenics. Arcturus Therapeutics' average media sentiment score of 1.65 beat MacroGenics' score of -0.09 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArcturus Therapeutics beats MacroGenics on 10 of the 16 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.42M$10.40B$5.49B$9.52BDividend YieldN/A1.99%4.73%4.09%P/E Ratio-1.7818.4228.7523.81Price / Sales0.6529.01372.2066.02Price / CashN/A22.3135.4557.96Price / Book0.853.478.275.55Net Income-$66.97M$234.77M$3.25B$259.20M7 Day Performance-7.60%-4.82%-3.72%-4.64%1 Month Performance14.49%1.80%4.30%4.41%1 Year Performance-58.75%-12.51%25.87%17.95% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.1882 of 5 stars$1.58+1.3%$5.33+237.6%-60.5%$98.42M$152.43M-1.78430Upcoming EarningsAnalyst DowngradeGap DownARCTArcturus Therapeutics3.0347 of 5 stars$13.79+2.1%$54.00+291.6%-43.0%$366.13M$152.31M-5.45180Positive NewsGLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.83-1.9%$15.33+163.0%+9.6%$365.37M$75.62M72.8890Gap DownHUMAHumacyte1.7073 of 5 stars$2.30-1.3%$11.71+409.3%-73.5%$361.43M$1.57M-3.33150News CoverageGap DownCYRXCryoPort2.1548 of 5 stars$6.71-6.7%$10.88+62.1%-16.4%$360.49M$228.38M-2.871,186Upcoming EarningsGap DownINBXInhibrx Biosciences1.3548 of 5 stars$22.12-9.5%N/A+48.2%$353.94M$200K0.19166TNXPTonix Pharmaceuticals3.4271 of 5 stars$45.10-3.9%$585.00+1,197.1%-24.9%$345.13M$10.09M0.0050Analyst RevisionGap DownFHTXFoghorn Therapeutics2.4956 of 5 stars$6.10-0.5%$12.13+98.8%-23.3%$341.70M$22.60M-4.49120Upcoming EarningsGap DownCADLCandel Therapeutics2.1933 of 5 stars$6.57-2.5%$22.00+234.9%+13.5%$337.69M$120K-4.9060AURAAura Biosciences1.556 of 5 stars$6.77+0.9%$22.00+225.0%-31.6%$337.30MN/A-3.5650Gap DownABEOAbeona Therapeutics3.5248 of 5 stars$6.75+2.4%$19.25+185.2%+34.9%$337.12M$3.50M-5.3190News Coverage Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Humacyte Alternatives CryoPort Alternatives Inhibrx Biosciences Alternatives Tonix Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Candel Therapeutics Alternatives Aura Biosciences Alternatives Abeona Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts